The fear is loud, and the data backs it up. According to the Nationwide Retirement Institute’s 2025 Social Security Survey, 83% of Americans currently receiving or expecting to receive Social Security are concerned about the program’s future. That worry is not happening in a vacuum. The Social Security Administration’s own trustees project that the Old-Age ... Nationwide Survey: 83% of Americans Are Worried Social Security Won’t Survive, and Here’s What to Do About It

These companies pay some of the world's most bankable dividends.

Warren Buffett stepped down as CEO of Berkshire Hathaway (BRK-B) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire. The “Oracle of Omaha” left his successor, Greg Abel, with a very concentrated portfolio: more than 65% of Berkshire’s $381 billion portfolio is ... Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold

Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.

Johnson & Johnson (NYSE:JNJ) has launched its global "Generation Fine" campaign to address depression care and improve patient conversations. The company reported new FDA approvals and positive Phase 3 data in immunology and neuropsychiatry, alongside progress on its OTTAVA robotic surgery platform. JNJ outlined an accelerated global registration plan for JNJ-1900 in head and neck cancer. The dual target antibody JNJ-4804 for inflammatory bowel disease did not meet its main Phase 2b...

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.

They have combined for 118 years of consecutive dividend increases.

J & J Snack Foods (NASDAQ:JJSF) reported fiscal second-quarter 2026 results that showed margin expansion and higher adjusted earnings despite a decline in sales, as management pointed to benefits from its “Project Apollo” transformation and ongoing portfolio reshaping. Chief Executive Officer D